Intersect ENT has agreed to acquire Fiagon AG Medical Technologies – Click here to learn more

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Third Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2019 .
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 17, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release third quarter financial results on November 1, 2019 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2019 Results
CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 15, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019 .
View HTML
Toggle Summary Intersect ENT Announces Appointment of Thomas A. West as CEO
Toggle Summary Intersect ENT Announces Publication of a Pooled Analysis of the SINUVA Sinus Implant for Nasal Polyps
Toggle Summary Intersect ENT Reports First Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 6, 2019-- Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019 .
View HTML
Toggle Summary Intersect ENT Announces CEO Transition Plan
Toggle Summary Intersect ENT to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 25, 2019-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at the Encore Hotel in Las Vegas , including a Q&A session at 1:40 p.m.
View HTML
Toggle Summary Intersect ENT to Report First Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 23, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release first quarter financial results on May 6, 2019 .
View HTML